Resultater fra humane metabolismeforsøg in vitro tyder på, at lenalidomid ikke metaboliseres af cytochrom- P450- enzymer, hvilket indikerer, at administration af lenalidomid sammen med lægemidler, som hæmmer cytochrom- P450- enzymer, formentlig ikke medfører metaboliske lægemiddelinteraktioner hos mennesker.
Results from human in vitro metabolism studies indicate that lenalidomide is not metabolised by cytochrome P450 enzymes suggesting that administration of lenalidomide with drugs that inhibit cytochrome P450 enzymes is not likely to result in metabolic drug interactions in man.